Martin de Bock
Overview
Explore the profile of Martin de Bock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Burckhardt M, Addala A, de Bock M
Front Endocrinol (Lausanne)
. 2024 Apr;
15:1400240.
PMID: 38596223
No abstract available.
12.
Wilkinson T, Tomic D, Boyle E, Burren D, Elghattis Y, Jenkins A, et al.
BMJ Open
. 2024 Feb;
14(2):e078171.
PMID: 38382954
Introduction: Multiple automated insulin delivery (AID) systems have become commercially available following randomised controlled trials demonstrating benefits in people with type 1 diabetes (T1D). However, their real-world utility may be...
13.
Leadley C, Addala A, Berkeley J, Crocket H, Davis E, Hewapathirana N, et al.
Front Endocrinol (Lausanne)
. 2023 Nov;
14:1270517.
PMID: 38033993
While advancements in the treatment of diabetes continue to rapidly evolve, many of the newer technologies have financial barriers to care, opposing the egalitarian ethos of Banting who sold his...
14.
Bowden N, Dixon R, Anderson V, de Bock M, Boucsein A, Kewene-Edwards M, et al.
Diabetologia
. 2023 Oct;
67(1):62-73.
PMID: 37870651
Aims/hypothesis: Type 1 diabetes is one of the most common chronic diseases of childhood. It is hypothesised that the metabolic and psychosocial consequences of type 1 diabetes may affect educational...
15.
Wilkinson T, de Bock M
J Diabetes Sci Technol
. 2023 Oct;
18(4):897-898.
PMID: 37850586
In an article in , Nanayakkara and colleagues assessed the glycemic efficacy and safety of AndroidAPS, an open-source automated delivery (AID) system, in a crossover randomized controlled trial. Although the...
16.
Sehgal S, de Bock M, Jones S, Frewen C, Wheeler B
Front Endocrinol (Lausanne)
. 2023 Sep;
14:1214975.
PMID: 37693343
Introduction: To evaluate the experiences of patients with type 1 diabetes following transition from a calibration-requiring to a calibration-free sensor and remote monitoring in the context of using automated insulin...
17.
Sehgal S, Elbalshy M, Williman J, Galland B, Crocket H, Hall R, et al.
J Diabetes Sci Technol
. 2023 Sep;
19(2):415-425.
PMID: 37671754
Aim: Real-time continuous glucose monitoring (rtCGM) has several advantages over intermittently scanned continuous glucose monitoring (isCGM) but generally comes at a higher cost. Do-it-yourself rtCGM (DIY-rtCGM) potentially has benefits similar...
18.
Sehgal S, Boucsein A, Styles S, Palmer O, Paul R, Crocket H, et al.
Diabet Med
. 2023 Jul;
41(2):e15168.
PMID: 37393600
Aims: In many countries, real-time continuous glucose monitoring (rt-CGM) is not funded, and cost presents a barrier to access. A do-it-yourself conversion of intermittently scanned CGM (DIY-CGM) is a cheaper...
19.
Burnside M, Haitana T, Crocket H, Lewis D, Meier R, Sanders O, et al.
J Diabetes Metab Disord
. 2023 May;
22(1):861-871.
PMID: 37250371
Purpose: Open-source automated insulin delivery (AID) is used by thousands of people with type 1 diabetes (T1D), but has unknown generalisability to marginalised ethnic groups. This study explored experiences of...
20.
Abraham M, Smith G, Choo A, de Bock M, Davis E, Jones T
Diabetes Technol Ther
. 2023 Apr;
25(8):549-553.
PMID: 37053526
Continuous glucose monitoring (CGM) systems are used in therapeutic decisions for diabetes management, however, the impact of body composition on CGM accuracy is not known. Body composition variables (body mass...